BusinessT2 · Outlet report
AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm…
1 update1 source1 mention here
Aug 3, 2026
Latest: AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger · The Guardian

